Loading
Multidisciplinary tumour boards are regular meetings where surgeons, oncologists, radiologists and pathologists review each patient's case with the full dataset and agree a plan before treatment starts. They are mandatory in the UK and for accreditation in the US, Europe and Germany, and change the diagnosis or plan in 10 to 30% of cases, though randomised evidence is lacking.
Multidisciplinary team (MDT) meetings became mandatory in the UK after the Calman-Hine report (1995) and are required for accreditation by the ACoS Commission on Cancer, OECI and German certified centres. Observational evidence links MDT review to changed diagnoses or plans in 10-30% of cases, better staging completeness, higher guideline adherence and, in some cohorts, improved survival (e.g. colorectal, lung, oesophageal), though randomised evidence is lacking. Molecular tumour boards (since ~2012) interpret genomic profiling; virtual and regional MDTs extend expertise to smaller hospitals; AI-assisted case preparation and decision support (e.g. Watson for Oncology, later withdrawn) have been tested. Challenges: time cost, variable quality, patient absence from discussion.
Structured, prospective case review by all relevant specialties with the full dataset (imaging, pathology, molecular, comorbidity) to produce a consensus, guideline-referenced recommendation before treatment starts.
One technology page on OnCo cites this paper by its DOI; this record gives the citation a page of its own so a reader can follow it without leaving OnCo. Read the abstract above alongside the citing page listed under Related; the record was created automatically from the Europe PMC entry and its figures have not been checked by hand.
One technology page on OnCo cites this paper by its DOI; this record gives the citation a page of its own so a reader can follow it without leaving OnCo. Read the abstract above alongside the citing page listed under Related; the record was created automatically from the Europe PMC entry and its figures have not been checked by hand.
Query for this technology: (TITLE:"Multidisciplinary tumour boards" OR ABSTRACT:"Multidisciplinary tumour boards") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Multidisciplinary tumour boards, not a curated reading list.
Shares Nodal marginal zone lymphoma, Splenic marginal zone lymphoma, Nodular lymphocyte-predominant Hodgkin lymphoma (nodular lymphocyte-predominant B-cell lymphoma), Nodal T-follicular helper cell lymphoma, angioimmunoblastic type (angioimmunoblastic T-cell lymphoma).
Shares Nodal marginal zone lymphoma, Splenic marginal zone lymphoma, Nodular lymphocyte-predominant Hodgkin lymphoma (nodular lymphocyte-predominant B-cell lymphoma), Nodal T-follicular helper cell lymphoma, angioimmunoblastic type (angioimmunoblastic T-cell lymphoma).
Shares Nodal marginal zone lymphoma, Splenic marginal zone lymphoma, Nodular lymphocyte-predominant Hodgkin lymphoma (nodular lymphocyte-predominant B-cell lymphoma), Nodal T-follicular helper cell lymphoma, angioimmunoblastic type (angioimmunoblastic T-cell lymphoma).
Shares Nodal marginal zone lymphoma, Splenic marginal zone lymphoma, Nodular lymphocyte-predominant Hodgkin lymphoma (nodular lymphocyte-predominant B-cell lymphoma), Nodal T-follicular helper cell lymphoma, angioimmunoblastic type (angioimmunoblastic T-cell lymphoma).
Shares Nodal marginal zone lymphoma, Splenic marginal zone lymphoma, Nodular lymphocyte-predominant Hodgkin lymphoma (nodular lymphocyte-predominant B-cell lymphoma), Nodal T-follicular helper cell lymphoma, angioimmunoblastic type (angioimmunoblastic T-cell lymphoma).
Shares Nodal marginal zone lymphoma, Splenic marginal zone lymphoma, Nodular lymphocyte-predominant Hodgkin lymphoma (nodular lymphocyte-predominant B-cell lymphoma), Nodal T-follicular helper cell lymphoma, angioimmunoblastic type (angioimmunoblastic T-cell lymphoma).
Shares Nodal marginal zone lymphoma, Splenic marginal zone lymphoma, Nodular lymphocyte-predominant Hodgkin lymphoma (nodular lymphocyte-predominant B-cell lymphoma), Nodal T-follicular helper cell lymphoma, angioimmunoblastic type (angioimmunoblastic T-cell lymphoma).
Shares Telehealth and hospital-at-home in oncology, Nodal marginal zone lymphoma, Splenic marginal zone lymphoma, Nodular lymphocyte-predominant Hodgkin lymphoma (nodular lymphocyte-predominant B-cell lymphoma).
Open-source projects that implement or serve this technology, from OnCo's own catalogue: licence and last activity as the repository reported them on the day of the fetch. Listing is not endorsement; check the licence before reuse and the validation before clinical use.
A cBioPortal extension for documenting molecular tumour board recommendations, from the German PM4Onco project.
Commercial and regulated products that serve this technology. Each card says what is behind it: a regulator's database, the literature, a public body's list, or only the company's own words. Listing is not endorsement, and a clearance is a regulatory fact, not a clinical one.
A service that gathers a patient's records from every institution that holds them, structures them, and puts the result in front of a virtual tumour board.
A non-profit that gives people with advanced cancer a scientist to work their case and a route to expert opinions, free at the point of use.
A case review workspace aimed at cancer foundations and their clinical teams, bringing a person's records, reports, imaging and genomic results into one place alongside trial search.
The cancer multidisciplinary team and pathway management system many NHS trusts run beside their main record, used to track referrals, meetings and waiting-time targets.